106 results about "SIGLEC" patented technology

Methods and compositions for treating fibrosis (e.g., cardiac fibrosis), or other conditions associated with inflammation and / or fibrosis are provided. Methods can include administering a nucleic acid encoding a sialic acid-binding immunoglobulin-type lectin 9 (Siglec-9) protein to a subject in need of fibrosis treatment, where the Siglec-9 protein is expressed by the nucleic acid in regulatory T (Treg) cells in the subject. Methods and compositions can include Treg cells that overexpress Siglec-9 to enhance the ability of Treg cells to target cells expressing amine oxidase, copper containing 3 (AOC3), including fibroblasts or myofibroblasts. In some embodiments, the enhanced Treg cells are targeted to myofibroblasts (e.g., cardiac myofibroblasts) with elevated expression of fibrotic genes.

The invention relates to the technical field of biomedical materials, in particular to engineered small extracellular vesicle hydrogel enriched with PD-L1 and Siglec-15 as well as a preparation method and application of the engineered small extracellular vesicle hydrogel. The engineering small extracellular vesicle hydrogel is enriched with PD-L1 and Siglec-15 at the same time, the engineering small extracellular vesicle hydrogel comprises a hydrogel base body and PDL1-Siglec15-sEVs loaded in the hydrogel base body, and the PDL1-Siglec15-sEVs are small extracellular vesicles with the PD-L1 and the Siglec-15 in an overexpression mode. Compared with natural small extracellular vesicles and a traditional wound surface treatment strategy, the engineered small extracellular vesicle hydrogel has the advantages that PD-L1 and Siglec-15 can be enriched in the vesicles, so that more accurate immune microenvironment regulation and control can be realized on the local part of a wound surface, excessive inflammatory response is moderately inhibited, phenotype transformation of macrophages to be beneficial to tissue regeneration is promoted, and the wound surface treatment effect is improved. The hydrogel is used as a carrier and can provide a moist healing environment and a three-dimensional scaffold structure, so that the residence time of the engineered small extracellular vesicles on the local wound surface is remarkably prolonged, and slow release is realized.

Undesirable mast cell activity is associated with various diseases or conditions, such as allergy, inflammatory diseases, autoimmune diseases, and cancer. New and improved therapeutic agents that can target c-Kit and / or siglec-6 (e.g., for mast cell related diseases or disorders) still have been desired. Disclosed herein are molecules, such as antibodies and antibody fragments, capable of binding to c-Kit and / or siglec-6. Disclosed herein are molecules, such as antibodies and antibody fragments, capable of binding to c-Kit and / or siglec-6.

To create an antibody that inhibits an immune checkpoint function based on interaction between VSIG4 and Siglec-7 and exhibits antitumor activity, and to provide an anti-tumor immune response activator which includes the antibody as an active ingredient.SOLUTION: The present invention provides an anti-tumor immune response activator including an antibody that inhibits intermolecular interaction between VSIG4 and Siglec-7 or a functional fragment thereof.SELECTED DRAWING: Figure 9

Provided herein are Siglec-8 binding proteins, and methods of using Siglec-8 binding proteins to modulate the biological activity of Siglec-8.

Multi-specific binding proteins that bind to and kill human cancer cells expressing CD33 (Siglec-3) are described, as well as pharmaceutical compositions and therapeutic methods useful for the treatment of CD33 expressing cancer. The invention relates to multi-specific binding proteins that bind to human cancer cells expressing CD33 and exhibit high potency and maximum lysis of target cells compared to anti-CD33 monoclonal antibodies. The multi-specific binding proteins comprise a CD33-binding domain, an NKG2D-binding domain and a CD16-binding domain.

The present invention provides anti-Siglec-15 antibodies and antigen-binding fragments thereof as well as isolated nucleic acids, vectors, engineered cells, formulations thereof, and methods of use thereof for treating diseases including cancer and bone disease in a human subject. The invention is further directed to bispecific and multispecific antibodies, antibody-drug conjugates and chimeric antigen receptors derived from the anti-Siglec-15 antibodies and fragments thereof.

Provided herein are antibodies and antibody fragments relating to SIGLEC-8 and CD117. Provided herein are methods and compositions relating to SIGLEC-8 and / or CD117 libraries having nucleic acids encoding for a scaffold comprising a SIGLEC-8 and / or CD117 domain. SIGLEC-8 and / or CD117 libraries described herein encode for immunoglobulins such as antibodies.

The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a Siglec-7 protein, e.g., human Siglec-7 or a mammalian Siglec-7, and have improved and / or enhanced functional characteristics, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.

Provided herein are anti-Siglec-10 and Siglec-8 antibody compositions and combinations thereof, and their use in the treatment of neurodegenerative diseases.

The invention discloses an application of Siglec-10 / G or a fusion protein containing a Siglec-10 / G protein structure in preparation of a medicine for treating glioma. The application finds that Siglec-10 / G is a new key myeloid immune checkpoint molecule in a glioma immunosuppression microenvironment, and reveals a specific molecular mechanism that Siglec-10 / G and related action signals (such as MUC1, CKB and GOT1) thereof influence glioma generation. The Rebinant Mouse Siglec-10 (C-Fc) provided by the invention can be combined with a ligand on the surface of a tumor cell, so that endogenous Siglec-10 / G signal transduction on MDM is competitively blocked, the anti-tumor immunity of a tumor-bearing mouse is improved, the growth of glioma is inhibited, the survival time of the tumor-bearing mouse is prolonged, and the Rebinant Mouse Siglec-10 (C-Fc) can be used for treating glioma.

The present invention provides a lipid nanoparticle (LNP) formulation comprising at least one sialic acid (SA)-containing lipid. The LNP formulation can effectively bind to cell surface Siglec, transfect specific cells in vitro, and target specific cells in vivo. The present invention also provides a method for using the LNP composition described herein for pharmaceutical applications. For example, the LNP provided herein is useful for intracellular delivery of nucleic acid therapeutic agents to a subject.

The present application relates to the technical field of biomedical materials, in particular to an engineered small extracellular vesicle hydrogel enriched with PD-L1 and Siglec-15, and a preparation method and application thereof. The engineered small extracellular vesicle hydrogel is simultaneously enriched with PD-L1 and Siglec-15, and comprises a hydrogel matrix and PDL1-Siglec15-sEVs loaded in the hydrogel matrix, wherein the PDL1-Siglec15-sEVs are small extracellular vesicles overexpressing PD-L1 and Siglec-15. Compared with natural small extracellular vesicles and traditional wound treatment strategies, the engineered small extracellular vesicle hydrogel of the present application can realize more precise immune microenvironment regulation at the local wound by enriching PD-L1 and Siglec-15 in the vesicles, moderately inhibit excessive inflammatory response, promote the phenotype transformation of macrophages to a phenotype conducive to tissue regeneration, help smooth transition from the inflammatory stage to the proliferation and reconstruction stage, and the hydrogel as a carrier can provide a moist healing environment and a three-dimensional scaffold structure, significantly prolong the residence time of the engineered small extracellular vesicles at the local wound, and realize slow release.

The invention belongs to the technical field of biological pharmacy, and particularly discloses a Siglec-15 affinity peptide and application thereof. According to the invention, a phage display heptapeptide library high-throughput screening technology is adopted, Siglec-15 affinity peptide 7-8 is obtained through multiple rounds of screening, and the Siglec-15 affinity peptide 7-8 is optimized and modified to obtain a reversed sequence flip peptide d-7-8. Experimental results show that the Siglec-15 affinity peptide can be used for affinity of Siglec-15 protein and blocking the interaction between Siglec-15 and a ligand Sialyl-Tn of Siglec-15, so that the anti-tumor effect is achieved; an in-vitro cell level experiment shows that the Siglec-15 affinity peptide has a relieving effect on inhibition of Siglec-15 on CD8 + T cell proliferation, has an obvious immune activation effect, does not have obvious toxic or side effects, can be used for preparing an anti-tumor drug or a detection reagent taking Siglec-15 as a target spot, and has a relatively good medical application prospect.

The present invention provides anti-Siglec-9 antibodies and antigen-binding fragments thereof as well as isolated nucleic acids, vectors, engineered cells, formulations thereof, and methods of use thereof for treating diseases including cancer and bone disease in a human subject. The invention is further directed to bispecific and multispecific antibodies, antibody-drug conjugates and chimeric antigen receptors derived from the anti-Siglec-9 antibodies and fragments thereof.

The present invention provides anti-Siglec-9 antibodies and antigen-binding fragments thereof as well as isolated nucleic acids, vectors, engineered cells, formulations thereof, and methods of use thereof for treating diseases including cancer and bone disease in a human subject. The invention is further directed to bispecific and multispecific antibodies, antibody-drug conjugates and chimeric antigen receptors derived from the anti-Siglec-9 antibodies and fragments thereof.

The present invention provides compositions comprising anti-Siglec antibodies and nucleic acid molecules encoding the same, and methods for treating or preventing a disease or disorder using the same.

The invention discloses a dual-regulation pharmaceutical composition for sepsis treatment, a preparation method and application, and belongs to the technical field of biological medicine, and the pharmaceutical composition comprises doxorubicin liposome, all-trans retinoic acid phospholipid complex nanoparticles and antibiotics. Preferably, the doxorubicin liposome is prepared from the sialic acid modified doxorubicin liposome, the sialic acid modified all-trans retinoic acid phospholipid compound nanoparticles and meropenem. Dynamic monitoring of myeloid-derived suppressor cells MDSCs and sialic acid binding immunoglobulin type lectin-E (SiglecE) positively expressed myeloid-derived suppressor cells, namely SiglecE + MDSCs cell subsets, in the middle and later periods of sepsis is used as an evaluation index of the immunosuppression state, and dual regulation and control of sepsis acute inflammation and immunosuppression are achieved. The method has remarkable advantages in the aspects of increasing the survival rate, precisely targeting immunosuppression, improving the drug delivery efficiency and the like, and a brand new solution is provided for clinical treatment of sepsis.

The application discloses a nanobody against sialic acid-binding immunoglobulin-like lectin 15 and a related biomaterial and application thereof, and belongs to the technical field of immunotherapy biological medicine. The nanobody against sialic acid-binding immunoglobulin-like lectin 15 or an antigen-binding fragment thereof provided by the application comprises three complementarity determining regions CDR1, CDR2 and CDR3, the nanobody is S1, the amino acid sequence of CDR1 of the S1 is SEQ ID No. 6, the amino acid sequence of CDR2 of the S1 is SEQ ID No. 7, and the amino acid sequence of CDR3 of the S1 is SEQ ID No. 8. The nanobody against sialic acid-binding immunoglobulin-like lectin 15 provided by the application can play a role in the development of a therapeutic drug for a cancer patient with high expression of Siglec-15.

The present invention provides natural killer engagers specific for activating natural killer cells through binding to Siglec-7, and nucleic acid molecules encoding the same, and methods for treating or preventing a disease or disorder using the same.

Provided are siglec ligands and siglec conjugates. Also provided are methods of use of such conjugates, as well as pharmaceutical compositions thereof.

The application of the biomarker combination in the preparation of a drug for fulminant myocarditis belongs to the field of drugs. The application is characterized in that the biomarker combination comprises Siglec-5; the biomarker combination is further selected from the group consisting of sST2, PAI-1, Siglec-5, CD163, CD40, P-Cadherin, CD14, CTLA4. The application finds that the expression of the biomarker in the plasma of a patient with fulminant myocarditis is increased, and confirms the role of the biomarker as a drug target in relieving and / or improving fulminant myocarditis. The level of the biomarker can be controlled by a drug, the diagnosis and subsequent treatment of the disease can be more intensified, and the biomarker has great application value in clinical practice.

The present invention provides compositions comprising anti-Siglec-10 antibodies and nucleic acid molecules encoding the same, and methods for treating or preventing a disease or disorder using the same.

The present invention provides compositions comprising anti-Siglec antibodies and nucleic acid molecules encoding same, as well as methods for treating or preventing diseases or disorders using same.

This invention provides a kit and detection method for detecting the Siglec fusion mutation gene and the GBS pathogenic gene. It is used for rapid combined detection of the Siglec5 / 14 fusion mutation gene, a preterm birth susceptibility gene, and the GBS pathogenic gene. It can effectively assess the risk of gynecological reproductive tract infections, preterm birth in pregnant women, and infection in newborns. It solves the problem that existing kits only detect the conditionally pathogenic bacteria and have poor specificity for disease association. The detection using this kit is faster and more sensitive. The detection process is closed-loop, avoiding the additional operation of electrophoresis differentiation. It is low-cost and easy to promote.

Provided herein are Siglec-8 binding proteins and methods of using the Siglec-8 binding proteins to modulate the biological activity of Siglec-8.

To provide pigs that exhibit resistance to porcine reproductive respiratory syndrome virus (PRRSV). [Solution] This disclosure relates to a genetically modified pig in which at least one allele of the SIGLEC-1 gene is inactivated and / or at least one allele of the CD163 gene is inactivated. A genetically modified pig in which both alleles of the SIGLEC-1 gene and / or both alleles of the CD163 gene are inactivated is resistant to porcine reproductive respiratory syndrome virus (PRRSV). Methods for producing such transgenic pigs are also provided.

Multi-specific binding proteins that bind to and kill human cancer cells expressing CD33 (Siglec-3) are described, as well as pharmaceutical compositions and therapeutic methods useful for the treatment of CD33 expressing cancer. The invention relates to multi-specific binding proteins that bind to human cancer cells expressing CD33, and exhibit high potency and maximum lysis of target cells compared to anti-CD33 monoclonal antibodies.

Anti-Siglec-9 antibody molecules or binding fragments thereof are disclosed. These anti-Siglec-9 antibody molecules or binding fragments can be used to treat cancer, acute or chronic hepatitis B.

Undesired mast cell activities are linked with various diseases or disorders, such as allergies, inflammatory diseases, autoimmune diseases, and cancers. There remains a need for new and improved therapeutics (e.g., for mast cell associated diseases or disorders) that can target c-Kit and / or siglec-6. Disclosed herein are molecules, such as antibodies and antibody fragments, capable of binding to c-Kit and / or siglec-6.